Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities, Zhengzhou 450052, China; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities, Zhengzhou 450052, China; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, China.
Biomed Pharmacother. 2021 May;137:111402. doi: 10.1016/j.biopha.2021.111402. Epub 2021 Feb 26.
Long non-coding RNAs (lncRNAs), a newly identified class of non-coding RNA (ncRNA), are defined as RNA molecules at least 200 nucleotides in length that are not translated into proteins. LncRNAs contribute to a wide range of biological processes and are master regulators of disease occurrence, development, and response to therapy in human malignancies. The lncRNA prostate cancer‑associated transcript 6 (PCAT6) is upregulated in various human malignancies, including lung cancer, hepatocellular carcinoma, cervical cancer, osteosarcoma, glioblastoma, colorectal cancer, breast cancer, gastric cancer, gastrointestinal stromal tumors, and pancreatic ductal adenocarcinoma. High expression of PCAT6 is closely correlated with aggressive clinicopathological characteristics and poor prognosis in cancer patients, suggesting it is an oncogenic lncRNA. PCAT6 overexpression also facilitates cell proliferation, invasion, and migration while attenuating apoptosis, indicating that it might serve as a new prognostic biomarker and therapeutic target for malignancies. Here, we discuss the molecular mechanisms, regulatory functions, and potential clinical applications of PCAT6 in cancer.
长链非编码 RNA（lncRNA）是一类新发现的非编码 RNA（ncRNA），定义为至少 200 个核苷酸长度的 RNA 分子，不能翻译成蛋白质。lncRNA 参与广泛的生物学过程，是人类恶性肿瘤中疾病发生、发展和对治疗反应的主要调节因子。前列腺癌相关转录本 6（PCAT6）是在多种人类恶性肿瘤中上调的，包括肺癌、肝细胞癌、宫颈癌、骨肉瘤、胶质母细胞瘤、结直肠癌、乳腺癌、胃癌、胃肠道间质瘤和胰腺导管腺癌。PCAT6 的高表达与癌症患者侵袭性临床病理特征和不良预后密切相关，表明其是一种致癌 lncRNA。PCAT6 的过表达还促进细胞增殖、侵袭和迁移，同时抑制细胞凋亡，表明其可能成为恶性肿瘤的新的预后生物标志物和治疗靶点。在这里，我们讨论了 PCAT6 在癌症中的分子机制、调控功能和潜在的临床应用。
